logo
  • 首页
  • 学术期刊
  • 论文检测
  • AIGC检测
  • 热点
  • 更多
    • 数据

NivolumabImmune-mediated liver toxicity and end-stage liver disease: case report

被引:0
|
作者:
机构:
来源:
Reactions Weekly | 2021年 / 1836卷 / 1期
关键词:
D O I:
10.1007/s40278-021-88414-9
中图分类号:
学科分类号:
摘要:
引用
收藏
页码:595 / 595
相关论文
共 50 条
  • [1] NivolumabImmune-mediated colitis: case report
    Reactions Weekly, 2025, 2041 (1) : 308 - 308
  • [2] NivolumabImmune-mediated colitis: case report
    Reactions Weekly, 2020, 1793 (1) : 342 - 342
  • [3] NivolumabImmune-mediated colitis: case report
    Reactions Weekly, 2019, 1751 (1) : 293 - 293
  • [4] NivolumabImmune-mediated hepatitis: case report
    Reactions Weekly, 2017, 1658 (1) : 353 - 353
  • [5] NivolumabImmune-mediated colitis: case report
    Reactions Weekly, 2023, 1959 (1) : 509 - 509
  • [6] NivolumabImmune-mediated myocarditis: case report
    Reactions Weekly, 2021, 1875 (1) : 265 - 265
  • [7] NivolumabImmune-mediated pneumonitis: case report
    Reactions Weekly, 2018, 1712 (1) : 397 - 397
  • [8] NivolumabImmune-mediated myositis: case report
    Reactions Weekly, 2020, 1834 (1) : 208 - 208
  • [9] NivolumabImmune-mediated hepatitis: case report
    Reactions Weekly, 2020, 1789 (1) : 195 - 195
  • [10] NivolumabImmune-mediated hypophysitis: case report
    Reactions Weekly, 2022, 1908 (1) : 438 - 438
← 12345 →